A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy
 of SAGE-324 compared to placebo on upper limb tremor reduction in individuals with essential
 tremor (ET).
Inclusion Criteria:

 -  Participant has a diagnosis of ET, defined as isolated tremor syndrome consisting of
 bilateral upper limb action tremor for at least 3 years prior to screening, with or
 without tremor in other locations and absence of other neurological signs, such as
 dystonia, ataxia, or parkinsonism, isolated focal tremors (eg, voice, head), task- and
 position-specific tremors, sudden tremor onset or evidence of step-wise deterioration
 of tremor.

 -  Participant scores at least 1.5 for each of the six items that comprise the combined
 total upper limb TETRAS (total performance subscale part 4) with the total score for
 the dominant upper limb (the sum of the three items for either the right or left upper
 limb, whichever is dominant) being at least 5.5, at both Screening and predose on Day
 1.

 -  Participant is willing to discontinue medications taken for the treatment of ET within
 14 days or 5 half-lives prior to receiving IP. Medications taken for the treatment of
 ET that were discontinued prior to receiving IP may be resumed following Day 29.

 -  Participant has no clinically significant findings, as determined by the investigator,
 on Screening and pre-dose Day 1 physical examination including mental state
 examination (MSE) and neurologic examination, 12-lead electrocardiogram (ECG), or
 screening clinical laboratory tests.

 Exclusion Criteria:

 -  Participant has a presence of known causes of enhanced physiological tremor.

 -  Participant has had recent exposure (14 days prior to Day 1) to tremorgenic drugs.

 -  Participant has had direct or indirect injury or trauma to the nervous system within 3
 months before the onset of tremor.

 -  Participant has had a previous procedure for the treatment of ET, deep brain
 stimulation, brain lesioning, or magnetic resonance (MR)-guided procedure, eg,
 MR-guided focused ultrasound.

 -  Participant has historical or clinical evidence of tremor with psychogenic origin
 (including but not limited to eating disorders, major depression, etc.).

 -  Participant has history of suicidal behavior within 2 years or answers "YES" to
 questions 3, 4, or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at
 Screening or at Day 1 or is currently at risk for suicide in the opinion of the
 investigator.

 -  Participant has used any known moderate or strong cytochrome P450 3A4 and/or inducers
 within 14 days or 5 half-lives (whichever is longer) prior to Day 1 or consumed
 grapefruit juice, grapefruit, Seville oranges, pomegranates, tangelos, or St. John's
 Wort or products containing these within 30 days prior to Day 1. Use of mild
 cytochrome inhibitors and/or inducers may be permitted.

 -  Participant has concurrent or recent exposure (14 days or 5 half-lives, whichever is
 longer, prior to the Day 1 visit) to sedative/hypnotic drugs, stimulants,
 highly-caffeinated beverages or dietary supplements containing high doses of caffeine,
 or recent increase above regular daily consumption of caffeine.

 -  Participant currently uses or has used within 14 days or 5 half-lives (whichever is
 longer) prior to Day 1, any prescription or over-the-counter medication that is a
 substrate of the OATP1B1 transporter.